Mycophenolate mofetil (MMF)
Mycophenolate mofetil (MMF) is a pharmaceutical drug with 59 clinical trials. Currently 11 active trials ongoing. Historical success rate of 65.9%.
Success Metrics
Based on 27 completed trials
Phase Distribution
Phase Distribution
10
Early Stage
31
Mid Stage
16
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
62.8%
27 of 43 finished
37.2%
16 ended early
11
trials recruiting
59
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Clinical Trials (59)
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)
Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients
A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation
The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
A Dose Escalation Study in de Novo Renal Transplantation
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 59